Bionic virus structure vaccine combining novel coronavirus N protein and mRNA molecule encoding S1 antigen and preparation method thereof

By combining the N protein of the new coronavirus with the S1 antigen mRNA molecule and encapsulating it in lipid particles, a bionic virus structural vaccine was constructed, which solved the problem of low efficiency in entering cells and no N antigen in the existing mRNA vaccine, and achieved strong antibodies and T cell response improves the immune protection effect of the vaccine.

CN118515783BActive Publication Date: 2024-11-08WEIRUI BIOTECHNOLOGY (KUNMING) CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410727081.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-06-06
Publication Date
2024-11-08
Estimated Expiration
2044-06-06

AI Technical Summary

Technical Problem

When delivering the new coronavirus antigen, the existing mRNA vaccines have low efficiency and are non-specific in entering cells, and fail to fully utilize the specific T cell response caused by the N antigen of the viral nucleocapsid structural protein, affecting the immune protection effect.

Method used

Design a buffer system to bind the N protein of the new coronavirus with the mRNA molecule encoding S1 antigen to form a bead-like structure of chromatin-like, and wrap it through the LNP lipid carrier to form a lipid particle structure, and load eukaryotic expression on the surface of the particles. S1 protein, constructing a bionic virus structure vaccine.

Benefits of technology

This vaccine can not only induce strong anti-S antigen and anti-N antigen-specific antibodies, but also activate specific T-cell responses of anti-S and anti-N antigen, significantly improving the immune protection effect of the vaccine.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118515783B_ABST
    Figure CN118515783B_ABST
Patent Text Reader

Abstract

The present invention relates to a biomimetic virus structure vaccine combining a novel coronavirus N protein and an mRNA molecule encoding an S1 antigen and a preparation method thereof, and belongs to the field of biomedicine technology. In the present invention, the N protein of the novel coronavirus nucleocapsid structure purified by prokaryotic expression is first combined with an mRNA molecule encoding an S1 antigen in a buffer system to form a biosynthetic body of a chromatin-like beaded structure. The lipid particle structure formed by the biosynthetic body is wrapped with an LNP lipid carrier, and the eukaryotic expressed S1 protein is further loaded on the surface of the lipid particle structure wrapping the biosynthetic body to form a biomimetic virus structure vaccine, which can not only induce the host to produce strong specific antibodies against the S antigen after immunizing the animal, but also produce specific antibodies against the N antigen. The biomimetic virus structure vaccine can induce the body to produce strong specific T cell responses against the S antigen and the N antigen, and strengthen the protective effect of the vaccine immune response in virus attacks.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a bionic virus structure vaccine combining a novel coronavirus N protein and an mRNA molecule encoding an S1 antigen, and a preparation method thereof. Background Art

[0002] In the development and application of various anti-SARS-CoV-2 virus vaccines, mRNA vaccines are a new form of vaccine prepared in an artificially synthesized form that can express endogenous viral antigens in cells, thereby first activating the natural immune system and starting the body's antiviral immune response. It shows that its immune effect is significantly better than other inactivated vaccines and peptide vaccines. Existing studies have shown that the advantage of this vaccine is that it uses a nanolipid delivery system (lipidnanoparticles delivering system) to deliver replicative or non-autonomous replicative mRNA molecules that can rely on the intracellular translation expression system into the cytoplasm to express antigen proteins. In this process, first, different forms of exogenously introduced mRNA molecules and expressed antigen proteins bind to the pattern recognition receptors (PRR) of the natural immune system in the cell, activating the natural immune response system, thereby recruiting antigen-presenting cells in the tissue, including dendritic cells and macrophages, through the immune signal molecules released by the cells, phagocytizing the antigens expressed by the mRNA molecules in these cells, and thus presenting the processed antigens to the T cell system to activate the acquired immune response. Based on the fact that this complete process of activating natural immunity / acquired immunity by mRNA molecule expression produces a good immune response, it shows that mRNA vaccines have the potential to simulate the viral infection process and induce immune responses. However, it is worth noting that the lipid delivery system used by mRNA vaccines achieves mRNA delivery by fusing with different cell membranes in a non-specific manner. Therefore, compared with the way that viruses enter cells by combining proteins on their membrane surface with specific receptors on the cell surface, they have lower entry efficiency and non-specific entry into multiple cells.

[0003] Based on this, by analyzing the structure of SARS-CoV-2 virus, making full use of the characteristics of the spike protein on the surface of the virus as a neutralizing antigen and the ability to bind to the DC-SIGN receptor on the surface of dendritic cells and macrophages in addition to the ACE2 receptor, a virus-like structure VLS (virus-like-structure vaccine) vaccine was constructed, which encapsulates mRNA molecules with lipid carriers and carries S1 protein on the surface, and has been patented (publication number CN116139108A). However, based on the in-depth analysis of the structure of SARS-CoV-2 virus and the correlation analysis of its antigen spectrum and immune protection response during the infection of the host, a tendency is that in the analysis of the herd immune response to Covid-19, in addition to the S antigen being the focus of the immune system to identify and produce corresponding neutralizing antibodies to block the infection of the virus, the virus's nucleocapsid structural protein N antigen has also been found to be an important antigen molecule that can cause specific T cell responses of the immune system. This response is often associated with the host's formation of a killer T cell response that controls the proliferation of the virus. The antigens used in existing mRNA vaccines do not consider the use of N antigen components. Summary of the invention

[0004] Based on the conclusion of immunological analysis related to SARS-CoV-2 infection proposed in the background technology, the present invention has further designed a technology for constructing a complete structure of SARS-CoV-2 virus, based on the premise that the patent for the virus-like structure VLS vaccine (CN116139108A) has been obtained. First, in the buffer system designed by the present invention, the N protein, the main structural component of the viral nucleocapsid expressed by the prokaryote, is combined with the mRNA molecule encoding the S1 antigen to form a biosynthetic body of a chromatin-like beaded structure. After the ChIP experiment confirms that the N protein is completely combined with the mRNA molecule, it is wrapped with an LNP lipid carrier to form a lipid particle structure, and the eukaryotic expressed S1 protein is loaded on the surface of the lipid particle structure to form a biomimetic virus structure vaccine. After vaccine feature identification and comprehensive immunological analysis, it is confirmed that the obtained biomimetic virus structure vaccine can not only induce the host to produce stronger specific antibodies against the S antigen, but also produce specific antibodies against the N antigen. More importantly, the vaccine can induce the body to produce a strong specific T cell response against the S antigen and the N antigen, thereby enhancing the protective effect of the vaccine immune response in virus attack.

[0005] Based on this, the first purpose of the present invention is to provide a buffer system that can combine the new coronavirus N protein with the mRNA molecule encoding the S1 antigen to form a beaded, virus-like nucleocapsid biosynthetic body. The second purpose of the present invention is to provide a lipid particle structure encapsulating a biosynthetic body combined with the new coronavirus N protein and the mRNA molecule encoding the S1 antigen and a preparation method thereof; the third purpose of the present invention is to provide a biomimetic virus structure vaccine combined with the new coronavirus N protein and an mRNA molecule encoding the S1 antigen and a preparation method thereof.

[0006] The buffer system (the "buffer system" used in the present invention hereinafter refers to the buffer of this component unless otherwise specified) is obtained by dissolving NaAc, NaCl, MgCl2, DTT and Fucose in water as a solvent. The pH value of the buffer system is 6.0-6.4, and the concentrations of each substance are, respectively, NaAc, 20 mM; NaCl, 10 mM; MgCl2, 10 mM; DTT, 1 mM; Fucose, 0.001% w / v.

[0007] The method for preparing the biosynthetic body of the novel coronavirus N protein and the mRNA molecule encoding the S1 antigen uses the above-mentioned buffer system, comprising the following steps:

[0008] (1) Dissolve the S1 antigen mRNA encoding the new coronavirus in TE Buffer with a pH of 6.0-6.4 to a concentration of 1000ug / ml;

[0009] (2) Dissolve the prokaryotic expressed SARS-CoV-2 N protein in TE Buffer at pH 6.8-7.2 at a concentration of 200ug / ml;

[0010] (3) (3) Add the mRNA of step (1) and the N protein of step (2) to the above buffer system at a concentration ratio of 5:1, react at 35-39°C for 28-32 minutes, and obtain a biosynthetic body composed of the SARS-CoV-2 N protein and the mRNA molecule encoding the S1 antigen.

[0011] The method for preparing a lipid particle structure encapsulating a biosynthetic body combined with a novel coronavirus N protein and an mRNA molecule encoding an S1 antigen comprises the following steps:

[0012] (1) lipid DHA-1, DOTAP, DOPC and mPEG-DTA-1-2K are mixed in anhydrous ethanol at a molar ratio of 56:10:27:1.6; and the biosynthetic product of claim 4 is diluted with a buffer containing 20 mM NaAc, 10 mM NaCL, 10 mM MgCl2, 1 mM DTT and 0.001% (w / v) trehalose;

[0013] (2) Using the microfluidic device NanoAssemblr R Ignite TM Model preparation of lipid particle structure encapsulating biosynthetic body;

[0014] (3) removing ethanol from the lipid particle structure encapsulating the biosynthetic body prepared in step (2) to obtain a lipid particle structure encapsulating the biosynthetic body with a nitrogen-phosphorus molar ratio of 15-18:1.

[0015] The bionic virus structure vaccine combining the SARS-CoV-2 N protein and the mRNA molecule encoding the S1 antigen comprises a biosynthetic body combining the SARS-CoV-2 N protein and the mRNA molecule encoding the S1 antigen.

[0016] The bionic virus structure vaccine that combines the new coronavirus N protein with the mRNA molecule encoding the S1 antigen comprises a lipid particle structure encapsulated with a biosynthetic body with a nitrogen-phosphorus molar ratio of 15-18:1.

[0017] The method for preparing the bionic virus structure vaccine combining the novel coronavirus N protein and the mRNA molecule encoding the S1 antigen is obtained by loading the S1 protein into the lipid particle structure described in claim 6, specifically,

[0018] The lipid particle structure was added to the S1 protein at a concentration ratio of 4:1 according to the mRNA encoding the S1 antigen and the S1 protein, mixed by rotation at room temperature, and then placed at 4°C for 16 hours, and diluted with a buffer containing 20 mM NaAc, 10 mM NaCL, 0.001% w / v trehalose and 2.5% glycerol.

[0019] Beneficial effects of the present invention:

[0020] The buffer system designed by the present invention can combine the N protein of the prokaryotic expressed new coronavirus nucleocapsid structure with the mRNA molecule encoding the S1 antigen to form a chromatin-like beaded structure. After the ChIP experiment confirmed that the N protein was completely bound to the mRNA molecule, it was wrapped with an LNP lipid carrier to form a lipid particle structure, and the eukaryotic expressed S1 protein was loaded on the surface of the lipid particle structure to obtain a bionic virus structure vaccine. Structural feature identification and comprehensive immunological analysis confirmed that the bionic virus structure vaccine can not only induce the host to produce strong specific antibodies against the S antigen, but also produce specific antibodies against the N antigen. More importantly, the bionic virus structure vaccine can induce the body to produce strong specific T cell responses against the S antigen and the N antigen, thereby strengthening and improving the protective effect of the vaccine immune response in the virus attack experiment. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 is an electron microscope image of the biosynthetic body of Example 1 of the present invention;

[0022] Figure 2 It is a comparison of the mRNA content copy in the biosynthetic body obtained in Example 1 of the present invention;

[0023] Figure 3 This is an electron microscopic comparison of the lipid particle structure of Example 2 of the present invention and the LNP encapsulating mRNA;

[0024] Figure 4 The lipofectin-encapsulated biosynthetic body and lipid particle structure of Example 2 of the present invention were transfected into 293T cells, and the number of S1 mRNA copies in the supernatant was detected by IP qPCR at different time points;

[0025] Figure 5 The Lipofectin-encapsulated biosynthetic body and lipid particle structure of Example 2 of the present invention are transfected into 293T cells and the N protein in the eluate and permeate is detected by IP WB at different time points;

[0026] Figure 6 This is an electron microscope image of the bionic virus structure vaccine and VLS of Example 3 of the present invention;

[0027] Figure 7 This is the qPCR test result of the biomimetic virus structure vaccine of Example 3 of the present invention

[0028] Figure 8 This is the WB test result of the bionic virus structure vaccine of Example 3 of the present invention;

[0029] Fig. 9 The titers of binding antibodies and neutralizing antibodies after immunizing Balb / C mice with the lipid particle structure and biomimetic virus structure vaccine of Example 3 of the present invention;

[0030] Fig.10 These are the results of cellular immunity detection after animals were immunized with the bionic virus structure vaccine and VLS according to Example 3 of the present invention;

[0031] Fig.11 The viral loads in different tissues of mice immunized with the bionic virus structure vaccine of Example 3 of the present invention were measured. DETAILED DESCRIPTION

[0032] In order to make the purpose, technical solution and beneficial effects of the present invention clearer, the technical solution of the present invention will be described in detail below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative work are all within the scope of protection of the present invention.

[0033] In order to more clearly illustrate the present invention, it is described in detail through the following examples.

[0034] Example 1

[0035] A method for preparing a biosynthetic body combining a prokaryotically expressed novel coronavirus N protein and an mRNA molecule encoding an S1 antigen, as follows:

[0036] (1) Dissolve the SARS-CoV-2-encoding S1 antigen mRNA in TE Buffer at pH 6.2. The mRNA concentration is 1000ug / ml.

[0037] (2) Dissolve the prokaryotically expressed SARS-CoV-2 N protein in TE Buffer at pH 7.0. The concentration of N protein is 200ug / ml.

[0038] (3) Add the following buffer system at a concentration ratio of 5:1 for reaction:

[0039] Buffer system used (solvent is sterile enzyme-free water):

[0040] NaAc 20mM (pH=6.2)

[0041] NaCl 10mM

[0042] MgCl2 10mM

[0043] DTT 1mM

[0044] Fucose 0.001%w / v

[0045] Incubate at 37°C for 30 min and store at 4°C until needed.

[0046] The reaction obtained a biosynthetic body (hereinafter referred to as the biosynthetic body) consisting of the combination of the SARS-CoV-2 N protein and the mRNA molecule encoding the S1 antigen. The electron microscopic image shows that the biosynthetic body is a beaded, virus-like nucleocapsid structure (see Appendix Figure 1 ).

[0047] Using the modified ChIP-q-RT-PCR method, using the specific antibody of SARA-CoV-2 N protein, the biosynthetic bodies bound to mRNA were precipitated and collected, and the collected biosynthetic bodies were used with specific primers to quantitatively detect the mRNA copy number in the structure collected by anti-N protein antibody by q-RT-PCR method. The details are as follows:

[0048] (1) Add 2 μL of anti-SARS-CoV-2 N protein-specific antibody to 200 μL of biosynthetic sample and incubate at room temperature for 2 h.

[0049] (2) Add 30 μL of Suzhou Beaver IgG magnetic beads, mix thoroughly and rotate on a rotator for 20 min (15-20 rpm / min), then place it in a magnetic bead separator and let it stand for 2 min. At this time, the magnetic beads are adsorbed to the tube wall and the supernatant sample (penetration fluid) is slowly aspirated.

[0050] (3) Add 200 μL of the elution buffer in the kit and mix the magnetic beads thoroughly (elution buffer).

[0051] (4) Take 100 μL of the sample, penetration solution and eluent respectively, add 300 μL of Trizol extract, mix thoroughly, centrifuge at 12,000 rpm and 4°C for 10 min, take the supernatant and place it in a new EP tube, add 250 μL of isopropanol and mix well, let it stand at room temperature for 15 min, then centrifuge at 12,000 rpm and 4°C for 15 min, discard the supernatant, at which point a trace amount of white precipitate can be observed; add 500 μL of anhydrous ethanol solution for washing, centrifuge at 12,000 rpm and 4°C for 10 min, discard the supernatant ethanol solution and air dry at room temperature, then add 100 μL of sterile enzyme-free water to dissolve the RNA.

[0052] (5) The dissolved RNA was subjected to q-RT-PCR detection (Kit: Takara One Step PrimeScript™ RT-PCR Kit, Code No. RR064A). The mRNA molecule encoding the S1 antigen was used as the mRNA standard for gradient dilution, starting from 1 ng / μL and then diluted 10 times to 0.1 ng / μL-0.00000001 ng / μL. 2 μL of the penetration buffer and the eluent were taken for quantitative detection of the extracted RNA. The primers required for the detection are:

[0053] F:TGGATCTGGAGGGAAAGCAGGGCAACT;

[0054] R: CCGATTGGCAGATCCACCAGAGGTTC;

[0055] Probe primer: 5′-6FAM-ATGGCTACTTCAAGATCTATAGCAAGC -TAMRA-3′;

[0056] The reaction procedure is shown in the table below.

[0057] Table 1 q-RT-PCR reaction system

[0058]

[0059] Table 2 q-RT-PCR reaction procedure

[0060]

[0061] The results showed that compared with the positive control group (the mRNA extracted from the biosynthetic body was used as the positive control), the mRNA copy number in the biosynthetic body collected by precipitation with antibodies against the SARS-CoV-2 N protein was approximately 80% of that in the positive control ( Figure 2 ). This indicates that the buffer system designed in the present invention can effectively bind the N protein and the mRNA molecule to form a viral nucleocapsid bead-like structure.

[0062] Example 2

[0063] A method for preparing a lipid particle structure encapsulating the biosynthetic body of Example 1:

[0064] (1) Lipids DHA-1, DOTAP, DOPC and mPEG-DTA-1-2K were mixed in anhydrous ethanol at a molar ratio of 56:10:27:1.6; at the same time, the biosynthetic product of the virus-like nucleocapsid in which the N protein encapsulated the mRNA molecule obtained in Example 1 was diluted with a buffer containing 20 mM NaAc, 10 mM NaCL, 10 mM MgCl2, 1 mM DTT and 0.001% (w / v) trehalose.

[0065] (2) Using microfluidic devices (NanoAssemblr R Ignite TM Model), and the lipid microsphere system was prepared with the following parameters: FRR: 1:3; TFR: 20ml / min; waste vol: 0.65 + 0.05 ml / 3:9, to obtain a lipid particle system encapsulating the biosynthetic body.

[0066] (3) The lipid particle structure encapsulating the biosynthetic body prepared in step (2) is diluted with 30 volumes of A1 buffer. A1 buffer contains 20 mM NaAc, 10 mM NaCL, 0.001% (w / v) trehalose and 2.5% glycerol. After dilution, the solution is concentrated by ultrafiltration through a 100Kda ultrafiltration membrane to obtain a lipid particle structure encapsulating the biosynthetic body bound to mRNA with a nitrogen-phosphorus molar ratio of 15-18:1 (hereinafter referred to as "lipid particle structure").

[0067] The results of electron microscopy and physicochemical analysis of the prepared lipid particle structure showed that the lipid particle structure was not significantly different from conventional mRNA / LNP in shape, and both were spherical structures ( Figure 3 ). The physical and chemical characteristics are shown as a particle size of 100-150nm, a particle aggregation index (PDI) of less than 0.2 and a surface potential of 10-20mV (Table 3)

[0068] Table 3 Physical and chemical properties of lipid particle structure

[0069]

[0070] Analysis of biological characteristics of the obtained lipid particle structure:

[0071] In order to confirm the biological function of the biosynthetic body designed by us, which is formed by the combination of the prokaryotic expressed new coronavirus N protein and the mRNA molecule encoding the S1 antigen, the lipid delivery system and the transfection reagent lipofectin 2000 published in patent CN115998714A ("A lipid nanoparticle, delivery system and preparation method of the delivery system") were used as the control delivery system, and the biosynthetic body was encapsulated and transfected into 293 cells, and the lipid particle structure obtained in this example was transfected into cells at the same time, and the cells were collected at 20 minutes, 40 minutes, 60 minutes, 90 minutes, 120 minutes, and 180 minutes after transfection, and the cells were broken by ultrasonic instrument, the supernatant was collected, and the mRNA molecules encapsulated by the N protein were collected using the improved immunoprecipitation method, as follows:

[0072] (1) 293T cells were plated in a 6-well plate 24 h in advance, and the biosynthetic body was transfected into the 293T cells with Lipofectin 2000 (Lipofectin 2000 transfection system: 5 μg of the biosynthetic body of Example 1 was added to 500 μL of Opti-MEM buffer and mixed slowly; 15 μL of Lipofectin 2000 transfection reagent was added to 500 μL of Opti-MEM buffer and mixed slowly; then the two were mixed at room temperature for 10 min to form a 1 ml transfection system, the complete culture medium in the 293T cells was completely aspirated, and 1 mL of the transfection system was added); at the same time, 5 μg of the lipid particle structure of Example 2 was added to the 293T cells.

[0073] (2) Take the cells 20 min, 40 min, 60 min, 90 min, 120 min and 180 min after transfection, discard the cell supernatant, add 500 μL of PBS solution and ultrasonically disrupt for 10 min (power 30%, ultrasonic 10 s pause 10 s), then centrifuge at 12000 rpm and 4°C for 10 min, and take the supernatant.

[0074] (3) Take 200 μL of the supernatant from step (2), add 2 μL of anti-SARS-CoV-2 N protein-specific antibody, and incubate at room temperature for 2 h.

[0075] (4) Add 30 μL of Suzhou Beaver IgG magnetic beads, mix thoroughly and rotate on a rotator for 20 min (15-20 rpm / min), then place it in a magnetic bead separator and let it stand for 2 min. At this time, the magnetic beads are adsorbed to the tube wall and the supernatant sample (penetration fluid) is slowly aspirated.

[0076] (5) Add 200 μL of the elution buffer in the kit and mix the magnetic beads thoroughly (elution buffer).

[0077] q-RT-PCR was used to quantify the structural changes of lipid particles after entering the cells, as follows:

[0078] ① Take 100 μL of the supernatant, penetration solution and eluate after sample crushing, add 300 μL Trizol extraction solution, mix thoroughly, centrifuge at 12000rpm and 4℃ for 10 min, take the supernatant and place it in a new EP tube, add 250 μL of isopropanol and mix well, let it stand at room temperature for 15 min, then centrifuge at 12000rpm and 4℃ for 15 min, discard the supernatant, at this time a trace of white precipitate can be observed; add 500 μL of anhydrous ethanol solution for washing, centrifuge at 12000rpm and 4℃ for 10 min, discard the supernatant ethanol solution and dry it at room temperature, add 100 μL of sterile enzyme-free water to dissolve RNA.

[0079] ② The dissolved RNA was subjected to q-RT-PCR detection (Kit: Takara One Step PrimeScript™ RT-PCR Kit, Code No. RR064A), in which the mRNA molecule encoding the S1 antigen was used as the mRNA standard for gradient dilution, starting from 1ng / μL and then diluted 10 times to 0.1ng / μL-0.00000001ng / μL, and 2μL of penetration buffer was taken. The RNA extracted from the eluate was quantitatively detected. The primers required for the detection are:

[0080] F: TGGATCTGGAGGGAAAGCAGGGCAACT;

[0081] R: CCGATTGGCAGATCCACCAGAGGTTC;

[0082] Probe primer: 5′-6FAM-ATGGCTACTTCAAGATCTATAGCAAGC -TAMRA-3′;

[0083] The reaction procedure is shown in the table below.

[0084] Table 4 q-RT-PCR reaction system

[0085]

[0086] Table 5 q-RT-PCR reaction procedure

[0087]

[0088] Experiments have shown that 20 minutes after the conventional transfection reagent was introduced, the N protein components and mRNA molecules were completely decomposed, while the lipid particle structure was slower than the conventional transfection reagent, and the N protein components and mRNA dissociation did not occur until 40 minutes later ( Figure 4 Although the mechanism is still unclear, this phenomenon shows that after the lipid particle structure of the present invention enters the cell, its mRNA and N protein can respectively play their functions.

[0089] Immunoblotting:

[0090] (1) Take 40 μL of the above-mentioned permeate and eluate after immunoprecipitation after collecting samples at different time points, add 10 μL of loading buffer (SDS-PAGE 5X reducing loading buffer), and boil for 10 min.

[0091] (2) Take 10 μL of the treated sample and add it to the PAGE gel wells. Run the gel at 120 V for 15 min and 180 V for 30 min.

[0092] (3) After SDS-PAGE gel transfer, the membrane was blocked with PBS solution containing 5% skimmed milk powder at room temperature for 1 hour, and N protein-specific antibody (1:1000 diluted in PBS buffer) was added for incubation overnight; then washed 5 times at room temperature with PBST solution, 5 minutes each time; secondary antibody (1:5000 diluted in PBS buffer) was added for incubation at room temperature for 1 hour; then washed 5 times at room temperature with PBST solution, 5 minutes each time, and finally exposed to color by ECL. The results showed that the presence of N protein could not be detected in the IP eluate of the sample coated with conventional transfection reagent after 40 minutes, and the lipid particle structure was similar to that of conventional transfection reagent ( Figure 5 ).

[0093] Example 3

[0094] A method for preparing a bionic virus structure vaccine combining a novel coronavirus N protein and an mRNA molecule encoding an S1 antigen, comprising the following steps:

[0095] (1) The lipid particle structure obtained in Example 2 was added with S1 protein at a concentration ratio of 4:1 according to the amount of mRNA encoding S1 antigen and the amount of S1 protein (equivalent to 20 μg S1 mRNA and 5 μg S1 protein per dose of biomimetic virus structure vaccine), mixed at room temperature (15 rpm / min) for 30 min, and then placed at 4°C for 16 hours.

[0096] (2) The samples treated overnight were diluted with a buffer solution (NaAc 20 mM, NaCL 10 mM, trehalose 0.001% (w / v) and 2.5% glycerol) and the concentration of S1 mRNA was determined to be 20 μg per dose, thereby obtaining a biomimetic virus structure vaccine combining the SARS-CoV-2 N protein and the mRNA molecule encoding the S1 antigen (hereinafter referred to as the biomimetic virus structure vaccine loaded with S1 protein).

[0097] The morphological and physicochemical characteristics of the bionic virus structure vaccine loaded with S1 protein were tested. The electron microscope examination showed that the particles were also spherical particles (Figure 6). The parameters of its physicochemical characteristics were similar to those of the VLS disclosed in patent CN116139108A.

[0098] Testing of physical and chemical properties of biomimetic virus structure vaccines and VLS vaccines

[0099]

[0100] A modified immunoprecipitation method was used to detect its structural form as follows:

[0101] (1) Take 2 μL of anti-SARS-CoV-2 S1 protein specific antibody and add it to 200 μL of biomimetic virus structure vaccine sample and incubate at room temperature for 2 hours.

[0102] (2) Add 30 μL of Suzhou Beaver IgG magnetic beads, mix thoroughly and rotate on a rotator for 20 min (15-20 rpm / min), then place it in a magnetic bead separator and let it stand for 2 min. At this time, the magnetic beads are adsorbed to the tube wall and the supernatant sample (penetration fluid) is slowly aspirated.

[0103] (3) Add 200 μL of the elution buffer in the kit and mix the magnetic beads thoroughly (elution buffer).

[0104] (4) Take 100 μL of sample, penetration solution and eluent respectively, add 300 μL of Trizol extract, mix thoroughly, centrifuge at 12,000 rpm and 4°C for 10 min, take the upper supernatant and place it in a new EP tube, add 250 μL of isopropanol and mix well, let it stand at room temperature for 15 min, then centrifuge at 12,000 rpm and 4°C for 15 min, discard the supernatant, at this time a trace amount of white precipitate can be observed; add 500 μL of anhydrous ethanol solution for washing, centrifuge at 12,000 rpm and 4°C for 10 min, discard the supernatant ethanol solution and dry it at room temperature, add 100 μL of sterile enzyme-free water to dissolve the RNA.

[0105] (5) The dissolved RNA was subjected to q-RT-PCR detection (Kit: Takara One Step PrimeScript™ RT-PCR Kit, Code No. RR064A). The mRNA molecule encoding the S1 antigen was used as the mRNA standard for gradient dilution, starting from 1 ng / μL and then diluted 10 times to 0.1 ng / μL-0.00000001 ng / μL. 2 μL of the penetration buffer was taken, and the RNA extracted from the eluate was quantitatively detected. The primers required for the detection are:

[0106] F: TGGATCTGGAGGGAAAGCAGGGCAACT;

[0107] R: CCGATTGGCAGATCCACCAGAGGTTC;

[0108] Probe primer: 5′-6FAM-ATGGCTACTTCAAGATCTATAGCAAGC -TAMRA-3′;

[0109] The reaction system and reaction procedure are shown in the table below.

[0110] q-RT-PCR reaction system

[0111]

[0112] q-RT-PCR reaction procedure

[0113]

[0114] (6) Take 40 μL of sample, permeate and eluate, add 10 μL of loading buffer (SDS-PAGE 5X reducing loading buffer), and boil for 10 min;

[0115] (7) Take 10 μL of the treated sample and add it to the PAGE gel wells. Run the gel at 120 V for 15 min and 180 V for 30 min.

[0116] (8) After transfer through SDS-PAGE gel, block with PBS solution containing 5% skimmed milk powder at room temperature for 1 hour, add anti-SARS-CoV-2 N protein specific antibody and S1 protein specific antibody (1:1000 diluted in PBS buffer) respectively and incubate overnight; then wash with PBST solution at room temperature for 5 times, 5 minutes each time; add secondary antibody (1:5000 diluted in PBS buffer) and incubate at room temperature for 1 hour; then wash with PBST solution at room temperature for 5 times, 5 minutes each time, and finally develop color by ECL exposure.

[0117] The results of qPCR and WB tests showed that the structure of the bionic virus structure vaccine is a bionic virus particle structure containing mRNA bound to N protein inside and S1 protein outside ( Figure 7 and Figure 8 ).

[0118] Analysis of the immunological effect of the obtained bionic virus structure vaccine:

[0119] Our previous work (patent CN116139108A) shows that the anti-SARS-CoV-2 VLS vaccine that only encapsulates mRNA molecules and is loaded with S1 protein on the outside can provide stimulation to the immune system including endogenous and exogenous antigen signals in animal immunization, thereby causing antibodies to produce a strong immune response, especially the production of high-titer antibodies against the S antigen.

[0120] According to the 0-day and 21-day immunization mode, Balb / c mice were immunized by intramuscular injection with lipid particle structure (obtained in Example 2), biomimetic virus structure vaccine (obtained in Example 3) and VLS vaccine (patent CN116139108A). On the 28th day after booster immunization, tail vein blood was collected and serum was separated for detection of binding antibodies and neutralizing antibodies; at the same time, spleen lymphocytes were separated and sorted for ELISPOT detection of TL-4 and IFN-γ cellular immune responses.

[0121] According to the 0-day and 21-day immunization mode, K18-ACE2 transgenic mice were immunized with the bionic virus structure vaccine by intramuscular injection, and the virus (WT) was challenged 45 days after the booster immunization. The heart, liver, spleen, lung, kidney, brain, spinal cord, lymph nodes, nasal cavity and other tissues were collected for virus load detection 3 and 5 days after the challenge.

[0122] Combined antibody detection: The sera of the lipid particle structure and biomimetic virus structure vaccine groups 28 days after booster immunization were tested in parallel using ELISA kits for Omicron (B.1.1.529 / BA.4&BA.5) strain, WT strain, Alpha (B.1.1.7) strain, Beta (B.1.351) strain, Gamma (P.1) strain and Delta (B.1.617.2) strain;

[0123] Neutralizing antibodies: Neutralizing antibodies were detected in the serum WT strain virus 28 days after booster immunization of the lipid particle structure and biomimetic virus structure vaccine groups using the Vero cell system.

[0124] Immunological analysis showed that the biomimetic virus structure vaccine of the present invention can induce a strong humoral immune response, which is manifested in the binding antibodies against different types of SARS-CoV-2 antigens as high as 10 7 -10 8, and 10 2 -10 3 Neutralizing antibodies ( Fig. 9 ).

[0125] ELISPOT test: 28 days after booster immunization with the biomimetic virus structure vaccine and VLS vaccine groups, the spleens of mice were removed and ground, and lymphocyte separation fluid was used (4 ml of mouse lymphocyte separation fluid was added to a 15 ml centrifuge tube, and the cell fluid of the ground spleen was slowly added to the 15 ml centrifuge tube, taking care not to wash up the lymphocyte separation fluid in the lower layer; then placed in a horizontal centrifuge and centrifuged at 800 rpm for 30 min at room temperature, and the speed was adjusted to 3 up and 3 down); the middle layer of lymphocyte fluid was aspirated, washed once with 1640 serum-free medium, the supernatant was discarded, and then resuspended with serum-free medium to prepare the lymphocytes. Then, the pre-prepared plates for IFN-γ and IL-4 detection were washed 3 times with PBS to wake up the plates. The amount of cells added to the IL-4 detection was 2x10^5 cells / 100μL per well, and 1x10^5 cells / 100μL was added to the IFN-γ detection. 3μg / 100μL of S1-RBD peptides of different strains (BA.4&BA.5, B.1.1.529, BA.2.12.1, BA.2.75.2, BQ.1.1, XBB .1) and N protein (WT, BA.4, B.1.1.529), cultured in a 37℃ incubator for 36-40h, took out the plate for cold water cell rupture, added IFN-γ and IL-4 antibodies (diluted 1:1000 in PBS buffer), incubated at 37℃ for 1.5h, washed 4-5 times with PBS, then added the corresponding secondary antibody (diluted 1:1000 in PBS buffer), incubated at 37℃ for 1h, washed 4-5 times with PBS, and finally added the color developing solution for color development.

[0126] The results show that the bionic virus structure vaccine obtained by the present invention can induce strong specific T cell responses against S antigen and N antigen respectively ( Fig.10 ).

[0127] According to the 0-day and 21-day immunization mode, K18-ACE2 transgenic mice were immunized by intramuscular injection with the biomimetic virus structure vaccine, and the virus was challenged 45 days after the booster immunization (WT). The heart, liver, spleen, lung, kidney, brain, spinal cord, lymph node, nasal cavity and other tissues were taken for disease load detection 3 days and 5 days after the challenge. The results show that the biomimetic virus structure vaccine obtained by the present invention shows a better protective effect against virus attack, which can more significantly inhibit the virus load in various organs of the attacked animals (Figure 11) and avoid damage to organ tissues.

[0128] Finally, it should be noted that the above preferred embodiments are only used to illustrate the technical solutions of the present invention rather than to limit it. Although the present invention has been described in detail through the above preferred embodiments, those skilled in the art should understand that various changes can be made in form and details without departing from the scope defined by the claims of the present invention.

Claims

1. A buffer system, characterized in that The buffer system is obtained by dissolving NaAc, NaCl, MgCl2, DTT and Fucose in water as solvent, and the pH value of the buffer system is 6.0-6.4, wherein: NaAc20mM; NaCl10mM; MgCl210mM; DTT1mM; Fucose0.001%w / v; The buffer system can enable the SARS-CoV-2 N protein to combine with the mRNA molecule encoding the S1 antigen to form a beaded, virus-like nucleocapsid biosynthetic body.

2. A method for preparing a biosynthetic product of a novel coronavirus N protein and an mRNA molecule encoding an S1 antigen, using the buffer system as claimed in claim 1, characterized in that: The steps include: (1) Dissolve the mRNA encoding the S1 antigen of the new coronavirus in TE Buffer with a pH of 6.0-6.4 to a concentration of 1000ug / ml; (2) Dissolve the prokaryotic expressed SARS-CoV-2 N protein in TE Buffer at pH 6.8-7.2 at a concentration of 200 ug / ml; (3) Add the mRNA of step (1) and the N protein of step (2) to the buffer system of claim 1 at a concentration ratio of 5:1, react at 35-39°C for 28-32 minutes, and obtain a biosynthetic product of the SARS-CoV-2 N protein and the mRNA molecule encoding the S1 antigen.

3. A biosynthetic product obtained by the preparation method of claim 2, which is a combination of the SARS-CoV-2 N protein and the mRNA molecule encoding the S1 antigen.

4. A gene delivery system comprising the biosynthetic body of claim 3 and nanolipid particles; the nanolipid particles are composed of DHA-1, DOTAP, DOPC and mPEG-DTA-1-2K.

5. A method for preparing a lipid particle structure encapsulating the biosynthetic body according to claim 3, characterized in that: The following steps are involved: (1) lipid DHA-1, DOTAP, DOPC and mPEG-DTA-1-2K are mixed in anhydrous ethanol at a molar ratio of 56:10:27:1.6; and the biosynthetic product of claim 3 is diluted with a buffer containing 20 mM NaAc, 10 mM NaCL, 10 mM MgCl2, 1 mM DTT and 0.001% trehalose; (2) Using the microfluidic device NanoAssemblr R Ignite TM Model preparation of lipid particle structure encapsulating biosynthetic body; (3) removing ethanol from the lipid particle structure encapsulating the biosynthetic body prepared in step (2) to obtain a lipid particle structure encapsulating the biosynthetic body with a nitrogen-phosphorus molar ratio of 15-18:

1.

6. The lipid particle structure encapsulated with the biosynthetic body obtained by the preparation method of claim 5.

7. A method for preparing a bionic virus structure vaccine combining a novel coronavirus N protein and an mRNA molecule encoding an S1 antigen, characterized in that: The method is obtained by loading the S1 protein into the lipid particle structure according to claim 6, specifically, The lipid particle structure was added to the S1 protein at a concentration ratio of 4:1 according to the mRNA encoding the S1 antigen and the S1 protein, rotated and mixed at room temperature, and then placed at 4°C for 16 hours, and diluted with a buffer containing 20 mM NaAc, 10 mM NaCL, 0.001% w / v trehalose and 2.5% glycerol.